1kits(10Fiyɛliw) .
| A sɔrɔli: | |
|---|---|
| Hakɛ: | |
▎ GLP-3 Lajɛba
GLP-3 ye pepitiri fura kura ye. I n’a fɔ agoniste triple receptor, a bɛ baara kɛ glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) ani glucagon minɛbagaw kan waati kelen na. A bɛ mɔgɔ kelen-kelen bɛɛ dɛmɛ u ka girinya dɔgɔya a kɛtɔ ka dumuni nege labɛn cogo bɛɛ la, ka fasa bonya, ka kɔngɔ bali, ani ka fanga musaka caya.
Ka fara o kan, GLP-3 bɛ se ka dusukun ni farikoloɲɛnajɛ farati jiralan caman fana ɲɛ, i n’a fɔ tansiyɔn, ɛmoɲini sukaro, sunɔgɔ la sukaro, inisɔndiya, kolosinsinnan bɛɛ lajɛlen, kolosinsinnan minnu ka dɔgɔn, ani triglycérides. A bɛ nɔ ɲuman bila fana banabagatɔw la minnu ka sugunɛbilenni tɛ dɔlɔ ye, o bɛ kɛ sababu ye ka mɔgɔ fanba ka sugunɛ tulu hakɛ segin a cogo kɔrɔ la.
Ni aw ye a suma ni agoniste kelen walima fila ye, GLP-3 bɛ joli sukaro, farikolo girinya, a ɲɔgɔnnaw ɲɛnabɔ ka bɔ yɔrɔ caman na, a kɛtɔ ka GLP-1, GIP ani glucagon (GCG) minɛbaga saba baara waati kelen na. Hakilila la, a bɛ se ka farikoloɲɛnajɛ banaw ɲɛnabɔ ka ɲɛ kosɛbɛ, wa nafa kɛrɛnkɛrɛnnenw b’a la a fan dɔw la i n’a fɔ farikolo girinya dɔgɔyali, sugunɛbilenni dɔgɔyali, ani joli sukaro hakɛ jiginni.
GLP-3 minɛbaga caman ka jɛ-ka-baara kɛcogo b’a to a bɛ se ka kɛ ka tɛmɛ GLP-1 minɛbaga agoniste walima dual receptor agoniste kɔrɔlenw kan sukarodunbana labɛnni na ani farikolo girinya kɔlɔsili la, o bɛ furakɛli suguya kura di banabagatɔw ma minnu fasalen don ani sukarodunbana suguya 2 bɛ minnu na.
▎ GLP-3 Sɛgɛsɛgɛli
GLP-3 ka ɲininiw kɛcogo ye mun ye?
Fasa kɛra foroba kɛnɛyako gɛlɛyabaw dɔ ye bi jamana kɔnɔ. A bɛ se ka kɛnɛya gɛlɛya caman lase mɔgɔ ma i n’a fɔ farikoloɲɛnajɛ suguya 2, dusukunnabana, tansiyɔn jiginni, farikolojidɛsɛ, ani sugunɛbilenni min tɛ dɔlɔ ye. Ni fasa hakɛ bɛ ka caya ka taa a fɛ, furakɛli kura mago bɛ teliya la ka taa a fɛ minnu bɛ se ka farikolo girinya kunbɛn ka ɲɛ ani ka kɛnɛyako ɲɛ Hali ni ɲɛnamaya kɛcogo fɛɛrɛw, i n’a fɔ farikoloɲɛnajɛ caya ani dumunikɛcogo, olu ye fɛɛrɛ jɔnjɔnw ye farikolo girinya kunbɛnni na, a ka gɛlɛn kosɛbɛ baliku fasa banabagatɔ caman ma ka u farikolo girinya dɔgɔyali kuntaalajan mara.
GLP-3, i n’a fɔ agoniste sabatilen kura, o bɛ se ka baara kɛ glucagon ɲɔgɔnna pepitiri-1 minɛbaga kan (
GLP-1R), insulinotropic polypeptide receptor (GIPR) min bɛ tali kɛ sukaro la (GIPR), ani glucagon minɛbaga (GCGR). O baarakɛcogo min bɛ Kɛ ni jaabi caman ye, o bɛ nafa caman Di a ma farikolo girinya dɔgɔyali siratigɛ la. Ni aw ye a suma ni farikolojidɛsɛ furaw ye minnu bɛ baara kɛ furakisɛ kelen dɔrɔn de kan, GLP-3 bɛ se ka farikolo ka farikoloɲɛnajɛ kɛcogo ɲɛnabɔ ka ɲɛ [1] . GLP-3 bɛ mɔgɔ girinya dɔgɔya ni a bɛ ɔrimɔni caman minɛcogo ɲɛnabɔ, a tɛ nafa kabakoma jira dɔrɔn, nka a bɛ kɔnɔboli kɔlɔlɔ nɔgɔmanw fana sɔrɔ. Ka fara o kan, i n’a fɔ GLP-3 ye farikolojidɛsɛ fura ye min fanga ka bon kosɛbɛ ani a bɛ se ka kɛ jamanaden hakɛ caman ye ni a bɛ tali kɛ farikolojidɛsɛ fura kura wɛrɛw la.
GLP-3 ye mun ye?
GLP-3 ye pepitiri-1 (GLP-1) minɛbaga kura ye min bɛ baara kɛ waati jan kɔnɔ. A bɛ fɛn caman sɛmɛntiya ani ka ɲɛ ka da GLP-1 nafama sigicogo kan, wa a bɛ se ka siri kɛrɛnkɛrɛnnenya la GLP-1 minɛbaga la ani k’a baara, ka farikolo baara kɛ i n’a fɔ GLP-1 nafama ta, i n’a fɔ ka inisɔndiya bɔli sabati, ka sukaro bɔli bali, ka kɔnɔbara lankolonya bila kɔfɛ, ka dumuni nege dɔgɔya, a ɲɔgɔnnaw A kɛcogo ka bon farikoloɲɛnajɛ furakɛli la ani ka girinya kunbɛn.
GLP-3 ka baarakɛcogo ye mun ye?
GLP-3 ka baarakɛcogo bɛ bɔ a ka agoniste nɔw la minnu bɛ sɔrɔ a minɛbaga caman kan. A fɔlɔ, a ka agoniste nɔ min bɛ sɔrɔ glucagon-like peptide-1 receptor (GLP-1R) la, o bɛ se ka dɔ fara insuline bɔli kan, ka glucagon bɔli bali, ka joli sukaro hakɛ dɔgɔya, ani o waati kelen na ka kɔnɔbara lankolonya bila kɔfɛ, ka dɔ fara fasa kan, ka dumuni dunta dɔgɔya Filanan, a ka agoniste nɔ min bɛ sɔrɔ glucose-dependent insulinotropic polypeptide receptor (GIPR) la, o bɛ se ka insuline bɔli sabati, ka glucose baarakɛcogo ɲɛ, ani ka nɔ bila tulumafɛnw falenni na, ka tulumafɛnw bɔli bali ani ka tulumafɛnw sɔrɔli sabati Ka fara o kan, GLP-3 ka agoniste nɔ min bɛ glucagon receptor (GCGR) kan, a ka c’a la, o bɛ glycogenolyse ni gluconeogenesis sabati sugunɛ na, o bɛ dɔ fara joli sukaro hakɛ kan. Nka, GLP-3 ka baara la, o sukaro wulicogo in bɛ bɔ a la ni a minɛbaga fila tɔw nɔ ye, ka sɔrɔ ka tulumafɛnw bɔli sabati ani ka tulu dalajɛli dɔgɔya Nin wale kɛcogo min bɛ kɛ ni laɲini caman ye, o bɛ se ka kɛ sababu ye ka fasa furakɛ ka tɛmɛ farikolojidɛsɛ fura kelenw kan.
Ni GLP-3 ye nin farikolojɔlan saba ninnu baara waati kelen na, a bɛ se ka farikoloɲɛnajɛ kɛcogo caman kɛ ani ka furakɛli nɔw lase fasa ni banaw ma minnu bɛ tali kɛ o la. Joli sukaro hakɛ labɛnni siratigɛ la, ikomi GLP-1R ni GIPR baarakɛli bɛ inisɔndiya bɔli sabati ani ka sukaro bɔli bali, wa GCGR baarakɛli bɛ kunbɛn ni a minɛbaga fila tɔw nɔ ye, GLP-3 bɛ se ka joli sukaro hakɛ labɛn ka ɲɛ, o min nafa ka bon kosɛbɛ farikoloɲɛnajɛ suguya 2 furakɛli la [1, 2 ] Tumu dalajɛli dɔgɔyali siratigɛ la, GCGR baarakɛli bɛ tulumafɛnw bɔli sabati ani ka tulumafɛnw dalajɛli dɔgɔya, ka sɔrɔ GLP-1R baarakɛli bɛ dɔ fara fasa kan ani ka dumuni dunta dɔgɔya, o bɛ tulumafɛnw sɔrɔli dɔgɔya ka taa fɛ a Ka fara o kan, GLP-3 fana bɛ nɔ ɲuman bila sugunɛbilenni na min tɛ dɔlɔ ye. A bɛ se ka tulu hakɛ dɔgɔya sugunɛ na ani ka sugunɛ baara ɲɛ.


HbA1c, farikolo girinya, tansiyɔn, ani tulumafɛnw Kunnafoni ye fɛnw ye minnu ka dɔgɔn (ni filiw bɛ SEw jira) ka bɔ nafa sɛgɛsɛgɛli kulu la, fo ni a fɔra cogo wɛrɛ la.
Soso:PubMed [4] Ɲɛjirali dɔw.
GLP-3 b’a nɔw jira fan jumɛnw na?
GLP-3 bɛ nɔba jira fan caman na
Kisɛya dɔgɔyali nɔba : GLP-3 ye farikolojidɛsɛ nɔba jira kɛnɛyaso sɛgɛsɛgɛli caman na. Misali la, kɛnɛyaso ka sɛgɛsɛgɛli dɔ la min kɛra baliku 338 kan (Jastreboff AMM, 2023), banabagatɔ minnu furakɛra ni GLP-3 hakɛ danfaralenw ye, olu girinya dɔgɔyara kosɛbɛ dɔgɔkun 48 kɔnɔ. Olu la, banabagatɔ minnu tun bɛ miligaramu 12 tata hakɛ kulu la, olu farikolo girinya bɔra 24,2% la, wa banabagatɔ hakɛ caman ye girinya dɔgɔyali sɔrɔ hakɛ caman na. Misali la, banabagatɔ minnu ye miligaramu 4, miligaramu 8 ani miligaramu 12 ta, banabagatɔ 92%, 100% ani 100%, olu farikolo girinya dɔgɔyara 5% walima ka tɛmɛ o kan. Kalan wɛrɛ la [3] , sɛgɛsɛgɛli fila kɛra minnu kɛra ni mɔgɔw ye, minnu kɛra ni banabagatɔ 353 ye minnu ka farikoloɲɛnajɛ suguya 2 bɛ u la, olu y’a jira ko ni i ye a suma ni furakisɛ ta ye, GLP-3 bɛ se ka banabagatɔw farikolo girinya dɔgɔya kosɛbɛ ni kilogaramu 11,89 ye, ani fana ka ɛmoɲini glycété (HbA1C) dɔgɔya. Ka fara o kan, banabagatɔ balikuw ka kɔrɔbɔliw la minnu fasalen don ni farikoloɲɛnajɛ tɛ, GLP-3 ye banabagatɔw girinya dɔgɔya 24,2%, ani banabagatɔ 83% ye u farikolo girinya dɔgɔya 15% walima ka tɛmɛ o kan dɔgɔkun 48 kɔnɔ. Nin jaabi ninnu b’a jira ko GLP-3 bɛ se ka mɔgɔ farikolo girinya dɔgɔya.
Farikoloɲɛnajɛ suguya 2 furakɛli : GLP-3 fana bɛ se dɔw jira farikoloɲɛnajɛ suguya 2 furakɛli la. Kɛnɛyaso sɛgɛsɛgɛli dɔw la, GLP-3 y’a jira ko dɔ bɔra ɛmoɲini glycété (HbA1c) la ani ka girinya dɔgɔya min bɛ bɔ a tata hakɛ la. Misali la, sɛgɛsɛgɛli dɔ la, banabagatɔ minnu ka farikoloɲɛnajɛ suguya 2 bɛ u la, GLP-3 ye joli sukaro kunbɛnni nɔba jira. Ni aw ye a suma ni furakisɛ ta ye, ɛmoɲini glycété (émoglobine glycé) dɔgɔyara ni 1,64% ye [3] . Ka fara o kan, sɛgɛsɛgɛli dɔ la min kɛra ni mɔgɔw ye, min kɛra ni mɔgɔ fila ye, ni furakisɛ fila ye, ani kulu kelen-kelen bɛɛ ka fasa 2, baganw ka misali minnu bɛ ni farikoloɲɛnajɛ suguya 2 ye, GLP-3 furakɛli kɔfɛ, olu ye dɔ bɔ kosɛbɛ ɛmoɲini hakɛ la, wa u farikolo girinya fana dɔgɔyara cogo la min bɛ bɔ a tata hakɛ la O bɛ se ka kɛ fura in nɔ bɛɛ ye GLP-1, GCGR ani GIPR la, olu minnu bɛ sukaro sɛnɛcogo ni fanga balansi ɲɛ.
Dusukun ni jolisiraw faratiw ɲɛnabɔli : GLP-3 tɛ se ka farikolo girinya dɔgɔya dɔrɔn, nka a bɛ se ka dusukun ni jolisiraw faratiw fana ɲɛ, i n’a fɔ joli segin furakisɛw hakɛ ani joli segin furakisɛw hakɛ. O b’a jira ko jɛɲɔgɔnya gɛlɛn bɛ fasa ni dusukunnabana cɛ, wa GLP-3 bɛ se ka fasa banabagatɔw dusukun ni jolisiraw kɛnɛya sabati sira caman fɛ. Misali la, ni aw ye dɔ bɔ u hakɛ la minnu tɛ HDL-C, apoB ani LDLP ye, o bɛ se ka dɔ bɔ joli siraw la; ni jolisegindumuni sukaro hakɛ dɔgɔyali bɛ se ka joli sukaro hakɛ kunbɛnni ɲɛ banabagatɔw la minnu farikolo bɛ se ka farikoloɲɛnajɛ kɛ, o bɛ dusukun ni jolisiraw gɛlɛyaw dɔgɔya [3, 5,.
Sugunɛbilenni min tɛ dɔlɔ ye (NAFLD) furakɛli : GLP-3 ye pepitiri sabatilen agoniste kura ye min bɛ glucagon minɛbaga (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), ani glucagon-like peptide-1 receptor (GLP-1R) laɲini. Kɔlɔsiliw y’a jira ko GLP-3 bɛ se ka sugunɛbilenni furakɛ min tɛ dɔlɔ ye. Kalan dɔ la, sɛgɛsɛgɛli dɔ kɛra dɔgɔkun 48 kɔnɔ, min kɛra ni mɔgɔw ye, minnu kɛra ni farikolojɔli baarakɛbaliya ye, ani sugunɛ tuluma hakɛ ye ≥10% ye. Jateminɛw y’a jira ko dɔgɔkun 24 kɔnɔ, sugunɛ tulu yeli ɲɔgɔn kɔ ka bɔ a daminɛ na, mɔgɔ minnu furakɛra ni GLP-3 hakɛ danfaralenw ye (miligaramu 1, miligaramu 4, miligaramu 8, ani miligaramu 12) olu kɛra -42,9%, -57,0%, -81,4% ani -82,4% ye, k’a sɔrɔ furakisɛ kulu ta kɛra +0,3 % ye O b’a jira ko GLP-3 bɛ se ka furakɛli nɔba bila sugunɛbilenni na min tɛ dɔlɔ ye.
Kuncɛli la, i n’a fɔ agoniste triple receptor kura, GLP-3 bɛ sebaayaba jira fasa ni bana minnu bɛ tali kɛ a la. A bɛ se ka hadamadenw ka farikoloɲɛnajɛ labɛn ka bɔ yɔrɔ caman na ni a bɛ sukaro minɛbaga, insulinotropi polipɛtidi minɛbaga min bɛ tali kɛ sukaro la, ani pepitiri-1 minɛbaga min bɛ tali kɛ sukaro la, o baara, ka joli sukaro kunbɛnni ɲɛ, ka farikolo girinya dɔgɔya, ani ka tulumafɛnw sɛnɛcogo ɲɛnabɔ. GLP-3 bɔli ye furakɛli suguya kura lase banabagatɔw ma minnu fasalen don, farikoloɲɛnajɛ suguya 2 bɛ minnu na, a ɲɔgɔnnaw A jirala ko a bɛna dancɛw tigɛ laadala furaw la minnu bɛ mɔgɔ kelen-kelen agoniste agoniste, ka marifa barikama di walasa ka fasa ni farikoloɲɛnajɛ banaw gɛlɛyabaw ɲɛnabɔ minnu bɛ ka juguya ka taa a fɛ, ka furakɛli siraw yiriwa ka taa a fɛ, ka banabagatɔw ka ɲɛnamaya kɛcogo ɲɛ, ani ka sigida furakɛli dɔgɔya doni doni.
A sɛbɛnbaga ko la
Fɛn minnu kofɔlen dòn san fɛ, olu bɛɛ ɲinini Kɛra, k’u Labɛn ani k’u Lajɛ Cocer Peptides fɛ.
Dɔnniya gafe sɛbɛnbaga
Rosenstock J ye dɔnnikɛla ye min fanga ka bon kosɛbɛ furakɛli siratigɛ la, a ni baaradaw bɛ baara kɛ ɲɔgɔn fɛ kosɛbɛ i n’a fɔ Texas Iniwɛrisite Saheli-Tilebin-yanfan dɔgɔtɔrɔso ani Texas Iniwɛrisite Dallas. A bɛ ɲininiw kɛ fana santiriw la i n’a fɔ Kanada VIGOR Center ani Veloc Clin Res Ctr Med City.
A ka ɲininiw bɛ tali kɛ kɔnɔnatumuw ni farikoloɲɛnajɛw la, dusukun ni jolisiraw ni dusukunnakow la, furakɛlicogo la, ani furakɛli kɛcogo kɔrɔbɔli la, k’a sinsin farikoloɲɛnajɛ, fasa, ani furakɛli minnu bɛ tali kɛ o la ani furaw dilanni kan. J Rosenstock ye ɲɛtaa caman sɔrɔ kɛnɛyaso furakɛli la, a tɔgɔ dara ko ɲininikɛla min tɔgɔ bɔra kosɛbɛ k’a ta san 2017 la ka se san 2024. O b’a jira ko a ka baara ye nɔba bila a la ani ko a dɔnna kosɛbɛ. A ni ɲininikɛla caman ka jɛkafɔ sababu fɛ, a ye ɲinini jɔnjɔnw sɔrɔlenw baara ka ɲɛ ka kɛ kɛnɛyaso baarakɛcogo ye, ka farikoloɲɛnajɛ ni dusukunnabana banabagatɔw nafa ani ka furakɛli dɔnniya yiriwa. Rosenstock J tɔgɔ sɛbɛnnen bɛ citation (citation) ɲɛfɔli sɛbɛn kɔnɔ [4].
▎ Sɛbɛn minnu bɛ tali kɛ o la
[1] Kaur M, Misra S. Sɛgɛsɛgɛli fura dɔ seginnkanni GLP-3, o ye agoniste saba fura kura ye fasa furakɛli kama[J]. Erɔpu jamanaw ka furakɛli gafe, 2024,80(5):669-676.DOI:10.1007/s00228-024-03646-0.
[2] Jastreboff A. M., Kaplan L. M., Frias J. P., ani a ɲɔgɔnnaw. Triple-Hormone-Receptor Agonist GLP-3 ka ɲɛsin fasa ma - Fasa 2 sɛgɛsɛgɛli[J]. Angletɛri kura ka furakɛli gafe, 2023,389(6):514-526.DOI:10.1056/NEJMoa2301972.
[3] Lopez D. C., Pajimna J. T., Milan M. D., ani a ɲɔgɔnnaw. 7792 GLP-3 nafa ka bon farikolo girinya dɔgɔyali la ani a dusukun ni farikoloɲɛnajɛ nɔw balikuw la: Seginkanni sigilen ni a sɛgɛsɛgɛli[J]. Ɲɛnamaya kɛcogo ɲuman ka gafe, 2024,8(1):163-749.DOI:10.1210/jendso/bvae163.749.
[4] Rosenstock J, Frias J, Jastreboff A. M., ani mɔgɔ wɛrɛw. GLP-3, n’o ye GIP, GLP-1 ani glucagon receptor agoniste ye, farikoloɲɛnajɛ suguya 2 bɛ mɔgɔ minnu na: sɛgɛsɛgɛli min kɛra k’a sɔrɔ a ma kɛ cogo si la, min kɛra ni fiyentɔ fila ye, min kɛra furakisɛ ye ani min bɛ kɛ ni wale ye, min bɛ kɛ ni kulu ye min bɛ taa ɲɔgɔn fɛ, fasa 2nan na, min kɛra USA[J Lancet, 2023,402(10401):529-544.DOI:10.1016/S0140-6736(23)01053-X. Bamako, Mali.
[5] Nicholls S, Pirro V, Lin Y, ani a ɲɔgɔnnaw. Triple-hormone receptor agonist GLP-3 bɛ lipoprotéines ni apolipoprotéines cogoya ɲɛ kosɛbɛ mɔgɔ minnu ka fasa walima minnu girinya ka ca[J]. Erɔpu dusukunnakow gafe, 2024,45.DOI:10.1093/eurheartj/ehae666.1501.
[6] Ray A. GLP-3: incretin minɛbaga saba bɛ fasa kunbɛnni na[J]. Sɛgɛsɛgɛli furaw kan dɔnnikɛlaw ka hakilina, 2023,32(11):1003-1008.DOI:10.1080/13543784.2023.2276754.
[7] Sanyal A. J., Kaplan L. M., Frias J. P., ani mɔgɔ wɛrɛw. Hormone récepteur saba GLP-3 ka ɲɛsin farikolojɔli baarakɛbaliya ma sugunɛbana fɛ: a kɛra sɛgɛsɛgɛli kɛcogo la min kɛra fasa 2a kɔnɔ[J]. Sigida furakɛli, 2024,30(7):2037-2048.DOI:10.1038/s41591-024-03018-2.
BƐƐRƐ KUNNAFONIW NI FƐRƐW KUNNAFONIW BƐƐ MIN BƐ NI WEBSITE KAN NA, U BƐ KUNNAFONIW FƆLƆ DƆRƆN NI KALANSENW YE.
Fɛn minnu bɛ di nin siti in kan, olu dabɔra ɲininiw dɔrɔn kama in vitro. Sɛgɛsɛgɛli in vitro (latinkan na: *in glass*, o kɔrɔ ye gilasi minɛnw na) bɛ kɛ hadamaden farikolo kɔkan. Nin fura ninnu tɛ furaw ye, Ameriki dumuniko ni furako ɲɛmɔgɔso (FDA) ma sɔn u ma, wa u man kan ka kɛ ka furakɛli bana, bana walima bana si bali, k’a furakɛ, walima k’a furakɛ. A dagalen don kosɛbɛ sariya fɛ ka nin fɛn ninnu don hadamaden walima bagan farikolo la cogo o cogo.